MAPT and Alzheimer disease: Metformin is an anti-diabetic drug that can activate AMPK, and improve cognitive dysfunction via reducing Aβ plaque loading and phosphorylated tau levels in AD models[114,120]; however, the role of Metformin in AD is controversial due to the lack of in-depth studies.